Advancing Hematology and Oncology Through Technology

Abstract: Genome sequencing technologies have been transformative in all fields of biology including agriculture, zoology, and especially human health. Cancer, as a putative genetically driven disease has been the focus of intense work, and actionable results, as a result of commoditization of genome sequencing. Although much of the low-hanging fruit of cancer genomics (e.g., simple mutations) has seemingly been picked, there remains considerable opportunity for the development of innovative techniques in basic and translational biology, detection, drug-resistance, and so on. In this talk, we will detail some of the cutting-edge methods our group has adopted or pioneered and the translational advances they may enable.

About the Speaker: James S Blachly, MD is an assistant professor of Internal Medicine in the Division of Hematology and Biomedical Informatics. As a physician-scientist also trained in mathematics and computer science, his lab marries sequencing technology with translational medicine to

(a) Understand the functional basis of disease – often, but not always leukemia
(b) Create better diagnostics for these diseases, and
(c) Develop and Improve treatments.

James S. Blachly, PhD
Friday, January 29th, 11:00am-12:00pm
Carmen Zoom